The Efamol Story

Our story began with a deep respect for nature and a curiosity in the vital role of omega fatty acids in our health. Since then, we've been pioneering the research and development of omega supplements to help you and your family flourish!

Future

Efamol continues to invest in further development and studies. Efamol will launch new formulas and products that hold our key values of quality, efficacy and ethical practice and help educate our audience in healthier living and wellbeing. 

Autumn 2019

Efamol is repositioned to become more environmentally sustainable and provide healthy lifestyle advice and guidance from our UK team of experts. We have removed unnecessary plastics from our packaging and are finding more sustainable ways to package, develop and distribute our products.

Spring 2019

A three year clinical research plan is commissioned at the University of Roehampton. Simon Dyall will continue his work with Efamol this time researching high EPA supplementation in young adults.

2015

Efamol commissioned two studies at the University of Roehampton with Professor Simon Dyall using Active Memory.  These studies focus on maintaining brain performance in older adults, they analyse the link between brain function and walking speed.

2014

The first study on Active Memory was completed. It assessed the effects of supplementation on maintaining brain function in older adults.

2007

Building on the success of Efalex Brain Formula, Efamol Active Memory was launched in the UK, a product specifically developed to maintain normal brain function and support working memory.

2006

Efamol was acquired by food supplement company, Wassen International Limited, to enable access to many more consumer markets across the globe.

1995

10 clinical studies were undertaken using Efalex Brain formula. Pioneered by Dr Jaqueline Stordy and Dr Alex Richardson into the importance of DHA for children's brain development and function.

1995

Efalex Brain Formula is launched. This scientifically developed formula was pioneering at the time, linking DHA blood levels to brain health in children.

1989

Over 30 clinical trials were undertaken globally using Efamol Evening Primrose Oil.

1981

The Efamol Research Institute was founded.  Consisting of leading Essential Fatty Acid experts globally.

1977

David Horrobin founded Efamol and launched Efamol Evening Primrose Oil.  Dr Horrobin developed Rigel seed, selectively grown to be 33% higher in GLA than standard Evening Primrose Oils.

Late 1950s

A group of researchers, including David Horrobin, studied the properties of GLA derived from the seed of the Evening Primrose plant.  They demonstrated that taking Efamol Evening Primrose Oil supplements increased levels of GLA in the body. They even took this knowledge to develop their own unique Evening Primrose plant (Rigel).
Title

Researched by experts

Efamol was founded by scientists in 1977 and has been pioneering research in omega fatty acid supplements ever since. 

Read our research
Dr Alex Richardson
DPhil (Oxon), PGCE, FRSA

Founder Director of the UK-based charity, Food and Behaviour (FAB) Research.

Dr Alex Richardson is a world-renowned researcher, educator, speaker and published author. Her main interests centre on the role of nutrition in brain health, and its implications for behaviour, learning and mood. 

7 clinical studies were undertaken by Dr Alex Richardson into the importance of DHA for brain development and function, funded by Efamol.
Dr Simon Dyall
PhD

Nutritional Neuroscientist, University of Roehampton

Dr Simon Dyall leads the MSc Clinical Neuroscience programme at the University of Roehampton, and is Honorary Research Fellow in the Centre for Neuroscience, Surgery and Trauma, Queen Mary University of London. He was twice elected to the Board of Directors of the International Society for the Study of Fatty Acids and Lipids (ISSFAL).

3 clinical studies were funded by Efamol. The studies researched the link between omega-3 polyunsaturated fatty acids (PUFAs) and mobility and brain function in ageing, mood and brain connectivity in young adults.